|
|
Volumn 3, Issue 2, 2002, Pages 273-276
|
|
Genaissance Pharmaceuticals, Inc.
|
|
Author keywords
Asthma; Cardiovascular disease; Cholesterol; Drug development; Drug discovery; Drug marketing; Drug response; Genomics; Haplotype; Informatics; Intellectual property; Pharmacogenomics; Psychiatry; Schizophrenia; SNP
|
|
Indexed keywords
ATORVASTATIN;
BETA 2 ADRENERGIC RECEPTOR;
CHOLESTEROL;
CLOZAPINE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MEVINOLIN;
PRAVASTATIN;
SALBUTAMOL;
SIMVASTATIN;
ARTICLE;
ASTHMA;
CARDIOVASCULAR DISEASE;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESPONSE;
DRUG SAFETY;
GENETIC ANALYSIS;
GENETIC VARIABILITY;
HAPLOTYPE;
HUMAN;
MARKER GENE;
PHARMACOGENOMICS;
PRESCRIPTION;
SCHIZOPHRENIA;
SINGLE NUCLEOTIDE POLYMORPHISM;
TECHNOLOGY;
COOPERATIVE BEHAVIOR;
DRUG INDUSTRY;
HUMANS;
VARIATION (GENETICS);
|
|
EID: 0036119430
PISSN: 14622416
EISSN: None
Source Type: Journal
DOI: 10.1517/14622416.3.2.273 Document Type: Article |
|
Times cited : (4)
|
|
References (2)
|
